IC
LGND icon

Innealta Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Innealta Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-367
Closed -$30.9K – 1002
2024
Q2 		$30.9K Buy
+367
New +$29.2K 0.01% 501

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Innealta Capital's LGND Position: Q3 2024 in Review

Innealta Capital sold out of Ligand Pharmaceuticals (LGND) in Q3 2024, closing a stake of 367 shares — an estimated $30.9K sold.

Innealta Capital first reported a position in LGND in Q2 2024 and held it in 1 quarter. The position peaked at $30.9K in Q2 2024. 243 funds tracked by Wall St. Rank hold LGND as of Q3 2024.

  • Innealta Capital reported no remaining Ligand Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 367 Ligand Pharmaceuticals shares in Q3 2024, an estimated $30.9K.
  • Innealta Capital first reported a position in Ligand Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's Ligand Pharmaceuticals position peaked at $30.9K in Q2 2024.
  • 243 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.